Skip to Content

Portola Regains Product Rights From Merck

From Associated Press (March 24, 2011)

NEW YORK -- Portola Pharmaceuticals Inc. will regain from Merck & Co. all of its rights to a potential stroke, the company said Thursday.

The drug candidate betrixaban is being designed to prevent stroke in patients with an abnormal heart rhythm.

"Regaining full rights to betrixaban represents a transformational opportunity for Portola," said William Lis, Portola’s CEO, in a statement.

The company most recently completed a midstage study. Merck said it returned rights to the drug as part of its ongoing "prioritization" process.

Portola is privately-held and based in South San Francisco, Calif. Merck is based in Whitehouse Station, N.J.


Posted: March 2011